Dana Hornbeak

Dr. Dana Hornbeak

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2018 in Advances in Therapy
Verified
Journal Article
Open access
PDF file
JMJonathan S. Myers
Jonathan S. Myers
IMImran Masood
Imran Masood
DHDana Hornbeak
Dana Hornbeak
JBJose I. Belda
Jose I. Belda
GAGerd Auffarth
Gerd Auffarth
LKL. Jay Katz
L. Jay Katz
Introduction This study evaluates long-term outcomes of two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin in eyes with refractory open angle glaucoma (OAG). Methods Prospective ongoing 5-year study of 80 eligible subjects (70 with 4-year follow-up) with OAG and IOP ≥ 18 mmHg after prior trabeculectomy and while taking 1–3 glaucoma medications. Subjects received two iStent® trabecular micro-bypass stents, one iStent Supra® suprachoroidal stent, and postoperative travoprost. Postoperative IOP was measured with medication and annually following medication washouts. Performance was measured by the proportion of eyes with ≥ 20% IOP reduction on one medication (the protocol-specified prostaglandin) versus preoperative medicated IOP (primary outcome); and the proportion of eyes with postoperative IOP ≤ 15 and ≤ 18 mmHg on one medication (secondary outcome). Additional clinical and safety data included medications, visual field, pachymetry, gonioscopy, adverse events, visual acuity, and slit-lamp and fundus examinations. Results Preoperatively, mean medicated IOP was 22.0 ± 3.1 mmHg on 1.2 ± 0.4 medications, and mean unmedicated IOP was 26.4 ± 2.4 mmHg. Postoperatively, among eyes without later cataract surgery, mean medicated IOP at all visits through 48 months was ≤ 13.7 mmHg (≥ 37% reduction), and annual unmedicated IOP was ≤ 18.4 mmHg (reductions of ≥ 30% vs. preoperative unmedicated IOP and ≥ 16% vs. preoperative medicated IOP). At all postoperative visits among eyes without additional surgery or medication, ≥ 91% of eyes had ≥ 20% IOP reduction on one medication versus preoperative medicated IOP. At month 48, 97 and 98% of eyes achieved IOP ≤ 15 and ≤ 18 mmHg, respectively, on one medication. Six eyes required additional medication, no eyes required additional glaucoma surgery, and safety measurements were favorable throughout follow-up. Conclusion IOP control was achieved safely with two trabecular micro-bypass stents, one suprachoroidal stent, and postoperative prostaglandin. This microinvasive, ab interno approach introduces a possible new treatment option for refractory disease. Trial Registration NCT01456390. Funding Glaukos Corporation.

2 June 2017 in Clinical & Experimental Ophthalmology
Verified
Journal Article
Open access
PDF file
JBJohn Berdahl
John Berdahl
LVLilit Voskanyan
Lilit Voskanyan
JMJonathan Myers
Jonathan Myers
DHDana Hornbeak
Dana Hornbeak
JGJane Ellen Giamporcaro
Jane Ellen Giamporcaro
TSThomas W Samuelson
Thomas W Samuelson
Importance: Additional data are sought regarding treatment options for glaucoma, a major cause of global blindness.Background: The study assessed outcomes following standalone implantation of two second‐generation trabecular micro‐bypass stents and postoperative topical prostaglandin in eyes with open‐angle glaucoma not controlled on two preoperative medications.Design: The study design is a prospective, nonrandomized, open‐label study at a tertiary‐care ophthalmology centre.Participants: Subjects had open‐angle glaucoma with preoperative intraocular pressure of 18–30 mmHg on two medications, a medication washout phase, and post‐washout intraocular pressure of 22–38 mmHg. All subjects (N = 53) have been followed for 18 months.Methods: One day following implantation of two second‐generation trabecular micro‐bypass stents, subjects started topical travoprost. Medication washout was repeated at month 12.Main Outcome Measures: The main outcome measure was the proportion of eyes with intraocular pressure reduction ≥ 20% versus medicated baseline intraocular pressure with reduction of one medication at 12 months.Results: At 12 months, 91% of eyes achieved intraocular pressure reduction ≥ 20% with reduction of one medication. All eyes had intraocular pressure ≤ 18 mmHg with reduction of one medication, and 87% had intraocular pressure ≤ 15 mmHg. Mean intraocular pressure on one medication was ≤ 13.0 mmHg (≥ 34% reduction) through 18 months. Mean post‐washout intraocular pressure at month 13 was 33% lower than preoperative unmedicated intraocular pressure. No adverse events occurred through 18 months.Conclusions and Relevance: In open‐angle glaucoma eyes on two preoperative medications, treatment with two second‐generation trabecular stents and one postoperative prostaglandin resulted in mean intraocular pressure ≤ 13 mmHg with reduction of one medication, with favourable safety. These findings show the utility of second‐generation trabecular bypass with postoperative prostaglandin in patients with open‐angle glaucoma.

20 October 2022 in Journal of Glaucoma
Verified
Journal Article
Open access
SSSteven R. Sarkisian
Steven R. Sarkisian
DGDavinder S. Grover
Davinder S. Grover
MGMark J. Gallardo
Mark J. Gallardo
JBJacob W. Brubaker
Jacob W. Brubaker
JGJane Ellen Giamporcaro
Jane Ellen Giamporcaro
FGfor the iStent infinite® Study Group
for the iStent infinite® Study Group
Précis:Purpose: Evaluate safety and effectiveness of the iStent infinite Trabecular Micro-Bypass System in patients with open-angle glaucoma (OAG) uncontrolled by prior surgical or medical therapy. Design: Prospective, multicenter, single-arm, open-label clinical trial. Methods: Implantation of iStent infinite (3 iStent inject W stents) was performed as a standalone surgical procedure in eyes with OAG uncontrolled by prior incisional or cilioablative surgeries or maximally-tolerated medical therapy (MTMT). Prospectively-declared effectiveness endpoints were proportion of eyes achieving ≥20% mean diurnal intraocular pressure (MDIOP) reduction from Baseline at Month 12 on the same or fewer IOP-lowering medication classes (responder endpoint) and mean change in MDIOP from Baseline at Month 12. Safety parameters included visual acuity, slit-lamp and fundus examinations, gonioscopy, perimetry, surgical complications, and adverse events. Results: Seventy-two eyes of 72 patients (mean age 71.9 y) with preoperative mean medicated MDIOP of 23.4±2.8 mmHg on a mean of 3.1±0.9 IOP-lowering medication classes were enrolled: 61 eyes with failed prior surgery/ies (Failed-Surgery subgroup) and 11 eyes uncontrolled on MTMT (MTMT subgroup). 76.1% of all enrolled patients met the responder endpoint (73.4% Failed-Surgery, 90.9% MTMT), with mean reduction (SE) in MDIOP at Month 12 of 5.9(0.6) mmHg (5.5(0.7) mmHg Failed-Surgery subgroup, 8.1(0.9) mmHg MTMT subgroup). For patients on the same or fewer medication as Baseline, 53.0% achieved ≥30% MDIOP reduction without surgical interventions/other events. Safety was favorable, with no explants, infection, or device-related interventions or hypotony. Conclusions: iStent infinite standalone surgery achieved clinically significant IOP reduction and favorable safety in patients with OAG uncontrolled by prior therapy.

1 August 2021 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
ISInder Paul Singh
Inder Paul Singh
SSSteven Sarkisian
Steven Sarkisian
DHDana Hornbeak
Dana Hornbeak
LKL Jay Katz
L Jay Katz
TSThomas Samuelson
Thomas Samuelson
Purpose: To examine effectiveness outcomes stratified by preoperative disease burden in the pivotal trial of iStent inject® with cataract surgery (INJ) vs cataract surgery alone (CS). Materials and Methods: Prospective, 3:1 randomized, single-masked, concurrently-controlled, multicenter trial enrolling 505 subjects with cataract and mild-to-moderate primary open-angle glaucoma who underwent iStent inject implantation with phacoemulsification or phacoemulsification alone, and were followed for 2 years including annual medication washouts. Post hoc stratification was completed for baseline mean diurnal intraocular pressure (BL DIOP; Low-DIOP < 25mmHg, Mid-DIOP ≥ 25 to < 30 mmHg, High-DIOP ≥ 30mmHg) and preoperative medication burden (Low-Med 1 medication, Mid-Med 2 medications, High-Med ≥ 3 medications). Results: The 24-month primary and secondary effectiveness endpoints were met, with significant treatment-over-control differences in percent of eyes achieving ≥ 20% unmedicated DIOP reduction and in unmedicated DIOP reduction, respectively. In subgroup analyses, the proportions of INJ eyes achieving the primary endpoint remained steady across all BL DIOP (75.4%, 77.1%, 74.4% in Low/Mid/High-DIOP strata, respectively) and preoperative medication levels (76.8%, 70.8%, 79.7% in Low/Mid/High-Med strata, respectively); meanwhile, the proportions of CS eyes diminished with higher BL DIOP (64.5%, 63.6%, 33.3%, respectively) and more medications (69.0%, 63.3%, 29.4%, respectively). Regarding secondary effectiveness, postoperative DIOP reduction increased with higher BL DIOP in INJ eyes (6.2mmHg, 7.8mmHg, 9.8mmHg, respectively) but plateaued in CS eyes (5.2mmHg, 5.8mmHg, 5.4mmHg, respectively). INJ eyes also had consistent DIOP reduction regardless of preoperative medication burden (6.8mmHg, 6.7mmHg, 7.8mmHg, respectively), while DIOP reduction diminished with more medications in CS eyes (6.1mmHg, 5.0mmHg, 3.3mmHg, respectively). Safety was favorable, comparable to phacoemulsification alone. Conclusion: Significant IOP reductions occurred across all levels of BL DIOP and preoperative medication burden in iStent inject eyes. DIOP reductions increased with higher BL DIOP and remained stable across all levels of preoperative medication burden, suggesting the device’s potential utility in more medically challenging cases.

7 April 2026 in Life
Verified
Journal Article
Open access
PDF file
STSavak Teymoorian
Savak Teymoorian
JKJasmin Kaur
Jasmin Kaur
DHDana Hornbeak
Dana Hornbeak
EBErik Barr
Erik Barr
This retrospective study evaluated real-world outcomes of standalone iDose TR intracameral travoprost implant administration. Sixty-five consecutive standalone iDose TR implantations performed by a single surgeon were analyzed. Patients were pseudophakic, had a diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT), and had a history of a prior non-filtering glaucoma procedure (e.g., selective laser trabeculoplasty [SLT] or bimatoprost intracameral implant) performed beyond the preceding 6 months. Intraocular pressure (IOP) and medications were measured for 12 months postoperatively. Subgroup analysis was stratified by history of SLT treatment and glaucoma severity. If target IOP was not attained, secondary minimally invasive glaucoma surgery was performed instead of reinitiating or adding medication, according to the surgeon’s standard practice. The analysis was by intention to treat. At 12 months, mean IOP reduced significantly to 14.0 ± 2.9 mmHg from a baseline of 20.0 ± 4.0 mmHg (−28%, p < 0.001). Eyes with IOPs ≤ 18, ≤15, and ≤12 mmHg increased significantly vs. baseline (36.9% to 92.3%, 10.8% to 73.8%, and 3.1% to 35.4%, respectively; all p < 0.001), and 89.2% of the eyes were medication-free vs. 87.7% preoperatively. Mean 12-month IOP reduction showed nonsignificant differences between eyes with or without prior SLT (−26% and −31%, respectively; p = 0.907) and among mild/OHT, moderate, or severe glaucoma eyes (−28%, −23%, and −34%, respectively; p = 0.085). Postoperatively, one case each of transient corneal edema and retinal edema were observed, which self-resolved without sequelae. Thus, standalone travoprost implant administration significantly reduced IOP over 12 months in OAG and OHT, while maintaining a low medication burden. Similar IOP reductions were observed regardless of prior SLT treatment and glaucoma severity.

Verified
Journal Article
Open access
PDF file
AYArkadiy Yadgarov
Arkadiy Yadgarov
DHDana Hornbeak
Dana Hornbeak
DDDeana Davidova
Deana Davidova
Background/Objectives: Evaluation of real-world outcomes of standalone implantation of the third-generation trabecular micro-bypass device (iStent infinite) in eyes with mild to severe primary open-angle glaucoma (POAG). Materials: This retrospective, uncontrolled consecutive case series included eyes undergoing standalone iStent infinite implantation at a single U.S. practice. Outcomes were assessed through 12 months, including changes in intraocular pressure (IOP) and medication burden (primary), proportions achieving IOP ≤ 12/15/18 mmHg and medication categories (secondary), and safety. Subgroup analyses were completed based on preoperative IOP, glaucoma severity, and medication burden. Results: Fifty-one eyes (mean age 66.5 ± 10.8 years) were included. Mean baseline IOP was 20.1 ± 5.4 mmHg on 2.1 ± 1.2 medications. At month 12, the mean IOP decreased to 16.0 ± 3.6 mmHg (−4.1 mmHg, −20.4%; p < 0.001), and mean medications decreased to 1.5 ± 1.2 (−28.6%; p < 0.001). The proportion of eyes achieving IOP ≤ 18/15/12 mmHg increased from 41.2%/15.7%/3.9% to 79.6%/42.9%/16.3%, respectively (all p < 0.001). Medication-free eyes increased from 15.7% to 30.6%, while eyes requiring ≥ 3 medications decreased from 47.1% to 20.4%. Eyes with baseline IOP > 18 mmHg achieved greater IOP reduction (−27.8%), whereas eyes with baseline IOP ≤ 18 mmHg maintained stable IOP with reduced medications. Kaplan–Meier analysis demonstrated 12-month freedom from incisional reintervention of 92.2%. No intraoperative complications occurred. Transient self-resolving hyphema was observed in 3.9% of eyes. A secondary incisional surgery was performed in four eyes (7.8%); no vision-threatening complications were reported. Conclusions: Standalone iStent infinite implantation resulted in significant IOP and medication reductions with a favorable safety profile over 12 months, with outcomes aligned with preoperative treatment goals. These results suggest potential benefit as a less invasive real-world glaucoma intervention, warranting confirmation in larger prospective studies.